(Govaere et al., 2022) The anti-CD163–IgG–dexamethasone strategy was applied on a rat high-fructose NASH model leading to significant reduction of inflammation, hepatocyte ballooning, fibrosis, and glycogen deposition. This evidence concerns the gene CD163 and metabolic dysfunction-associated steatohepatitis.